Novo Nordisk launches Tre­siba, new gen basal in­sulin in Kuwait

Kuwait Times - - HEALTH & SCIENCE -


Novo Nordisk has launched Tre­siba (in­sulin degludec) in Kuwait. Tre­siba is a on­cedaily basal in­sulin for peo­ple with di­a­betes that suc­cess­fully achieves equiv­a­lent re­duc­tions in blood glu­cose lev­els, with a lower risk of noc­tur­nal hy­po­gly­caemia ver­sus in­sulin glargine. Tre­siba al­lows for flex­i­bil­ity in day-to­day dos­ing time, when needed with­out com­pro­mis­ing ef­fi­cacy or risk of hy­po­gly­caemia.

One of the key chal­lenges with in­sulin ther­apy is the risk of hy­po­gly­caemia, when blood glu­cose lev­els fall to lower than nor­mal lev­els, caus­ing un­pleas­ant symp­toms, such as dizzi­ness and con­fu­sion, un­con­scious­ness and some­times leads to death. Re­search shows that fears and con­cerns about hy­po­gly­caemia can in­ter­fere with achiev­ing op­ti­mal gly­caemic con­trol in peo­ple with di­a­betes us­ing in­sulin8. Hy­po­gly­caemia that oc­curs at night is of par­tic­u­lar con­cern9 for peo­ple liv­ing with di­a­betes, as it is un­pre­dictable and dif­fi­cult to de­tect.

Re­sults from stud­ies over a two-year pe­riod show Tre­siba suc­cess­fully achieves equiv­a­lent re­duc­tions in HbA, but with a lower risk of noc­tur­nal hy­po­gly­caemia com­pared to in­sulin glargine.

“Main­tain­ing good blood glu­cose con­trol with in­sulin treat­ment can be chal­leng­ing for health­care pro­fes­sion­als and pa­tients due to con­cerns over hy­po­gly­caemia and night­time hy­po­gly­caemia in par­tic­u­lar. Tre­siba(r) has shown less risk of noc­tur­nal hy­po­gly­caemia than the most widely used basal in­sulin,” said Akin Ak­sek­ili, Gen­eral Man­ager Novo Nordisk Gulf. “Tre­siba can be ad­min­is­tered at any time of the day, of­fer­ing flex­i­ble dos­ing when needed. This flex­i­bil­ity could help im­prove the lives of pa­tients, as poor in­sulin ad­her­ence con­trib­utes to poor gly­caemic con­trol.” said Dr Waleed Al-Dahi - Pres­i­dent of Kuwait Di­a­betes So­ci­ety and Con­sul­tant En­docri­nol­o­gist at Mubarak Al-Kabeer Hospi­tal.

Com­pli­ca­tions from di­a­betes caused by fail­ing to keep op­ti­mal gly­caemic con­trol can be se­ri­ous, and may in­clude prob­lems such as heart dis­ease, stroke, blind­ness, kid­ney dis­ease, nerve dam­age and pre­ma­ture mor­tal­ity. In Kuwait, where al­most 400,000 peo­ple live with di­a­betes, 35.2 per­cent of these pa­tients with di­a­betes are still un­di­ag­nosed and the per­cent­age of di­a­betes-re­lated deaths that oc­cur in peo­ple un­der 60 years were 47 per­cent in 2015.

Newspapers in English

Newspapers from Kuwait

© PressReader. All rights reserved.